Madrigal Pharmaceuticals (MDGL) Net Income towards Common Stockholders (QoQ) (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Madrigal Pharmaceuticals 15.79 Bn 15.56 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 46.33%
Dec 31, 2025 -54.77%
Sep 30, 2025 -163.07%
Jun 30, 2025 42.33%
Mar 31, 2025 -59.75%
Dec 31, 2024 57.14%
Sep 30, 2024 29.62%
Jun 30, 2024 -3.00%
Mar 31, 2024 -31.51%
Dec 31, 2023 -13.63%
Sep 30, 2023 -15.08%
Jun 30, 2023 -11.58%
Mar 31, 2023 10.49%
Dec 31, 2022 -5.80%
Sep 30, 2022 -14.80%
Jun 30, 2022 -22.97%
Mar 31, 2022 10.89%
Dec 31, 2021 -2.30%
Sep 30, 2021 -2.35%
Jun 30, 2021 -16.72%